Abstract 547P
Background
Immunotherapy is now standard of care in advanced/metastatic lung cancer patients either in first line alone or in combination with chemotherapy, also in subsequent lines. Here, we presenting real world outcome with immunotherapy in lung cancer patients from India.
Methods
We performed an analysis of prospectively collected data of patients with advanced/metastatic lung cancer treated at a single academic cancer centre in India. The patient’s demographic data, treatment details, toxicity and response to treatment captured from electronic medical record of each patient. Data was analysed for safety and survival outcome.
Results
From August 2015 to September 2021, 164 eligible patients were included in this study. Median age at presentation was 59 year (range 21 year to 86 year). 82% (n=134) were male and 18% (n=34) were female (M: F 4.5:1). At presentation, 73% (n=118) were ECOG PS 0 or 1, 14.5% (n=24) were ECOG PS 2, and 12.5% (n=22) were ECOG PS 3 or 4. Out of 164, 33% (n = 54), received immunotherapy drug in first line, 46% (n = 76) in second line, 21% (n = 34) in third line and beyond. 65% (n=106) received Nivolumab, 26.5% (n=44) received Pembrolizumab, 8.5% (n=14) received Atezolizumab. Median progression free survival and median overall survival was 5 months (95% CI 3.5 to 6.5 month) and 10 months (95% CI 7.3 to 12.7 month) respectively. Overall, 3-year PFS and OS rate is 5% and 23%. Fatigue was most common seen in 15% patients, hyponatremia in 5.3%, anorexia in 2.4%. Among immune-related toxicity- pneumonitis was most common seen in 4.8%, followed by hypothyroidism in 3.8%, transaminitis and nephritis in 1.9% each, skin rash, colitis, and encephalitis in 1.4% each, adrenal insufficiency and hypophysitis in 1% each seen.
Conclusions
In real world, immunotherapy having clinically significant benefit on survival in advanced/metastatic lung cancer patients with acceptable safety profile including patients with borderline performance status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract